Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06925581

A Trial of HRS-6768 in Patients With Advanced Solid Tumors

A Phase I/II Clinical Trial to Evaluate the Pharmacokinetics, Radiation Dosimetry, Safety and Preliminary Efficacy of HRS-6768 in the Treatment of Patients With Advanced Solid Tumors

Status
Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
84 (estimated)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGHRS-6768HRS-6768

Timeline

Start date
2025-04-24
Primary completion
2026-04-01
Completion
2027-04-01
First posted
2025-04-13
Last updated
2025-12-03

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT06925581. Inclusion in this directory is not an endorsement.